文献速递前列腺增生与排尿功能障碍

联合药物治疗膀胱过度活动症的疗效与安全性:快速证据评估

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
PubMed 文献 · Eur Urol · 2019-08-13

该快速证据评估基于2018年6月的文献检索,纳入涉及两种抗毒蕈碱药或β3-肾上腺素受体激动剂联合抗毒蕈碱药治疗膀胱过度活动症(OAB)的研究。米拉贝隆联合索利那新在多项随机对照试验中显示可改善尿失禁发作、排尿次数及生活质量,且耐受性良好;双抗毒蕈碱药治疗的数据有限但提示对中重度症状患者有益。

要点

  • 米拉贝隆联合索利那新可有效改善OAB症状和生活质量,且耐受性良好。
  • 对索利那新5mg单药反应不足者,联合米拉贝隆50mg可进一步减少尿失禁发作。
  • 双抗毒蕈碱药治疗(如曲司氯铵+索利那新)有限数据提示对中重度症状有益。

核心结论

  • 米拉贝隆联合索利那新为OAB患者提供有效且耐受性良好的治疗。
  • 双抗毒蕈碱药治疗的有限数据提示对中重度症状患者有获益。

研究设计与样本

  • 快速证据评估,2018年6月检索Embase、MEDLINE和Cochrane数据库及会议摘要。
  • 纳入报告两种抗毒蕈碱药或β3-肾上腺素受体激动剂联合抗毒蕈碱药疗效/安全性的研究。
  • 关键证据来自三项12周随机对照试验(SYMPHONY、SYNERGY、BESIDE)和一项12个月随机对照试验(SYNERGY II),以及五项双抗毒蕈碱药研究。

主要发现

  • SYMPHONY显示联合治疗相比索利那新5mg和安慰剂在临床症状和生活质量上有统计学显著改善。
  • SYNERGY中米拉贝隆25mg或50mg联合索利那新5mg相比各自单药在尿失禁发作/24h和排尿次数/24h(共同主要终点)及次要疗效参数上一致改善。
  • BESIDE中索利那新5mg单药反应不足者,米拉贝隆50mg联合索利那新5mg相比索利那新5mg在尿失禁改善上更优(p=0.001)。
  • 联合治疗在减少尿失禁方面非劣于索利那新10mg,在改善排尿频率方面优于索利那新10mg(p<0.001),且OAB-5维度评分从基线改善优于索利那新5mg和10mg(p<0.01)。
  • SYNERGY II中米拉贝隆50mg联合索利那新5mg相比单药显示临床有意义且持续的改善。

关键数值与推荐

  • 四项试验中联合治疗均耐受良好,不良事件发生率组间相似,特定不良事件发生率无显著差异。

临床怎么用

  • 对于OAB患者,可考虑米拉贝隆联合索利那新以改善症状和生活质量。
  • 对索利那新5mg单药反应不足的患者,联合米拉贝隆50mg可能进一步减少尿失禁发作。

局限性

  • 双抗毒蕈碱药治疗的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Oral pharmacotherapy consisting of antimuscarinics, β3-adrenoreceptor agonists, or combinations of these agents forms the mainstay of overactive bladder (OAB) management. OBJECTIVE: To evaluate the efficacy and safety of combination therapy in patients with OAB. EVIDENCE ACQUISITION: A literature search was conducted in June 2018 using Embase, MEDLINE, and Cochrane databases via Ovid and relevant congress abstracts. Studies reporting the efficacy/safety of two antimuscarinics or a β3-adrenoreceptor agonist plus an antimuscarinic were included. EVIDENCE SYNTHESIS: Publications reported on clinical efficacy, safety, and health-related quality of life (HRQoL) for mirabegron (M) plus solifenacin (S) from three 12-wk randomised controlled trials (RCTs)-SYMPHONY, SYNERGY, and BESIDE-and a 12-mo RCT, SYNERGY II. SYMPHONY reported statistically significant improvements in clinical symptoms and HRQoL with combination therapy versus solifenacin 5 mg (S5) and placebo. In SYNERGY, there were consistent improvements in urinary incontinence (UI) episodes/24 h and micturitions/24 h (coprimary endpoints), and in secondary efficacy parameters with mirabegron 25 mg (M25) + S5 and mirabegron 50 mg (M50) + S5 versus respective monotherapies. In patients with an inadequate response to S5 monotherapy (BESIDE), greater improvements in UI (primary endpoint) were noted for M50 + S5 versus S5 (p = 0.001). Combination therapy was noninferior to solifenacin 10 mg (S10) for reduction in UI and superior to S10 for improvement in micturition frequency (p < 0.001), and resulted in greater improvements from baseline in OAB-5 Dimension scores versus S5 and S10 (p < 0.01). In SYNERGY II, clinically meaningful and sustained improvements in clinical outcomes were observed for M50 + S5 versus M50 or S5. Combination therapy was well tolerated in all four trials. The incidence of adverse events (AEs) was similar across groups, and there were no notable differences in the incidence of specific AEs. Positive efficacy outcomes were observed in five studies of dual antimuscarinic therapy (trospium + solifenacin). CONCLUSIONS: Mirabegron plus solifenacin provides effective, well-tolerated treatment for patients with OAB. Limited data for dual antimuscarinic therapy suggest a benefit in patients with moderate-to-severe symptoms. PATIENT SUMMARY: Overactive bladder (OAB) is treated with medicines called antimuscarinics, such as solifenacin, propiverine, or trospium, or another β-adrenoreceptor agonist medicine called mirabegron, which works in a different way. We looked at published scientific studies of patients with OAB treated with mirabegron plus solifenacin together, or with two antimuscarinics. We found that mirabegron plus solifenacin can help reduce symptoms and improve quality of life. Patients tolerate this treatment well, with few patients experiencing side effects.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gratzke C, Chapple C, Mueller ER, et al. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. Eur Urol. 2019. PMID: 31416636. doi:10.1016/j.eururo.2019.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。